vs
CHAMPIONS ONCOLOGY, INC.（CSBR）与REDWOOD TRUST INC（RWT）财务数据对比。点击上方公司名可切换其他公司
REDWOOD TRUST INC的季度营收约是CHAMPIONS ONCOLOGY, INC.的1.7倍（$25.9M vs $15.0M），REDWOOD TRUST INC净利率更高（77.2% vs 1.8%，领先75.4%），CHAMPIONS ONCOLOGY, INC.同比增速更快（11.5% vs -6.1%），过去两年CHAMPIONS ONCOLOGY, INC.的营收复合增速更高（11.8% vs -41.0%）
冠军肿瘤学公司是一家成立于2007年的美国科技企业，由约翰霍普金斯大学肿瘤学家David Sidransky博士创立。该公司开发名为TumorGrafts的小鼠模型（又称小鼠化身），可用于测试多种化疗方案、靶向药物与单克隆抗体，帮助为癌症患者筛选潜在的可行治疗方案。
Redwood Trust Inc是总部位于美国的专业房地产投资信托公司，主营住宅与商业抵押贷款、抵押贷款支持证券及房地产信贷类资产的投资管理，核心业务覆盖住宅抵押贷款发放、商业地产信贷和投资服务，客户以机构投资者和房地产市场参与者为主。
CSBR vs RWT — 直观对比
营收规模更大
RWT
是对方的1.7倍
$15.0M
营收增速更快
CSBR
高出17.5%
-6.1%
净利率更高
RWT
高出75.4%
1.8%
两年增速更快
CSBR
近两年复合增速
-41.0%
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $15.0M | $25.9M |
| 净利润 | $268.0K | $20.0M |
| 毛利率 | 51.7% | — |
| 营业利润率 | 1.2% | — |
| 净利率 | 1.8% | 77.2% |
| 营收同比 | 11.5% | -6.1% |
| 净利润同比 | -63.2% | 402.6% |
| 每股收益（稀释后） | $0.02 | $0.11 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSBRRWT
| Q4 25 | $15.0M | $25.9M | ||
| Q3 25 | $14.0M | $15.0M | ||
| Q2 25 | $12.4M | $13.8M | ||
| Q1 25 | $17.0M | $27.9M | ||
| Q4 24 | $13.5M | $27.6M | ||
| Q3 24 | $14.1M | $25.5M | ||
| Q2 24 | $14.0M | $67.4M | ||
| Q1 24 | $12.0M | $74.5M |
净利润CSBRRWT
| Q4 25 | $268.0K | $20.0M | ||
| Q3 25 | $-436.0K | $-7.7M | ||
| Q2 25 | $-1.8M | $-98.5M | ||
| Q1 25 | $4.5M | $16.1M | ||
| Q4 24 | $728.0K | $-6.6M | ||
| Q3 24 | $1.3M | $14.8M | ||
| Q2 24 | $-109.0K | $15.5M | ||
| Q1 24 | $-2.5M | $30.3M |
毛利率CSBRRWT
| Q4 25 | 51.7% | — | ||
| Q3 25 | 42.9% | — | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | — | ||
| Q4 24 | 44.9% | — | ||
| Q3 24 | 49.7% | — | ||
| Q2 24 | 48.2% | — | ||
| Q1 24 | 34.7% | — |
营业利润率CSBRRWT
| Q4 25 | 1.2% | — | ||
| Q3 25 | -3.8% | -9.0% | ||
| Q2 25 | -16.2% | -679.0% | ||
| Q1 25 | 26.4% | 80.2% | ||
| Q4 24 | 5.4% | -1.3% | ||
| Q3 24 | 9.5% | 86.1% | ||
| Q2 24 | -1.9% | 30.3% | ||
| Q1 24 | -21.4% | 41.3% |
净利率CSBRRWT
| Q4 25 | 1.8% | 77.2% | ||
| Q3 25 | -3.1% | -51.4% | ||
| Q2 25 | -14.9% | -712.0% | ||
| Q1 25 | 26.4% | 57.8% | ||
| Q4 24 | 5.4% | -24.0% | ||
| Q3 24 | 9.3% | 58.1% | ||
| Q2 24 | -0.8% | 23.0% | ||
| Q1 24 | -21.1% | 40.6% |
每股收益（稀释后）CSBRRWT
| Q4 25 | $0.02 | $0.11 | ||
| Q3 25 | $-0.03 | $-0.08 | ||
| Q2 25 | $-0.12 | $-0.76 | ||
| Q1 25 | $0.31 | $0.10 | ||
| Q4 24 | $0.05 | $-0.08 | ||
| Q3 24 | $0.09 | $0.09 | ||
| Q2 24 | $-0.01 | $0.10 | ||
| Q1 24 | $-0.19 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $255.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.2M | $982.6M |
| 总资产 | $30.2M | $23.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CSBRRWT
| Q4 25 | $8.5M | $255.7M | ||
| Q3 25 | $10.3M | $226.3M | ||
| Q2 25 | $9.8M | $302.0M | ||
| Q1 25 | $3.2M | $259.9M | ||
| Q4 24 | $2.8M | $245.2M | ||
| Q3 24 | $2.9M | $253.7M | ||
| Q2 24 | $2.6M | $275.6M | ||
| Q1 24 | $4.5M | $275.4M |
总债务CSBRRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $1.7B |
股东权益CSBRRWT
| Q4 25 | $4.2M | $982.6M | ||
| Q3 25 | $3.5M | $999.0M | ||
| Q2 25 | $3.8M | $1.1B | ||
| Q1 25 | $5.5M | $1.2B | ||
| Q4 24 | $681.0K | $1.2B | ||
| Q3 24 | $-332.0K | $1.2B | ||
| Q2 24 | $-1.9M | $1.2B | ||
| Q1 24 | $-2.1M | $1.2B |
总资产CSBRRWT
| Q4 25 | $30.2M | $23.7B | ||
| Q3 25 | $30.5M | $22.6B | ||
| Q2 25 | $32.3M | $21.3B | ||
| Q1 25 | $30.6M | $19.9B | ||
| Q4 24 | $25.2M | $18.3B | ||
| Q3 24 | $24.9M | $18.4B | ||
| Q2 24 | $26.1M | $16.5B | ||
| Q1 24 | $26.8M | $15.1B |
负债/权益比CSBRRWT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 1.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7M | $-10.1B |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | — |
| 自由现金流率自由现金流/营收 | -13.1% | — |
| 资本支出强度资本支出/营收 | 1.6% | — |
| 现金转化率经营现金流/净利润 | -6.47× | -504.15× |
| 过去12个月自由现金流最近4个季度 | $5.6M | — |
8季度趋势，按日历期对齐
经营现金流CSBRRWT
| Q4 25 | $-1.7M | $-10.1B | ||
| Q3 25 | $600.0K | $-2.7B | ||
| Q2 25 | $6.9M | $-2.1B | ||
| Q1 25 | $490.0K | $-2.0B | ||
| Q4 24 | $-283.0K | $-5.9B | ||
| Q3 24 | $311.0K | $-2.1B | ||
| Q2 24 | $-1.8M | $-2.0B | ||
| Q1 24 | $-919.0K | $-954.2M |
自由现金流CSBRRWT
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $554.0K | — | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | — | ||
| Q4 24 | $-377.0K | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $-1.8M | — | ||
| Q1 24 | $-1.0M | — |
自由现金流率CSBRRWT
| Q4 25 | -13.1% | — | ||
| Q3 25 | 4.0% | — | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | — | ||
| Q4 24 | -2.8% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -13.0% | — | ||
| Q1 24 | -8.4% | — |
资本支出强度CSBRRWT
| Q4 25 | 1.6% | — | ||
| Q3 25 | 0.3% | — | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.7% | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.8% | — |
现金转化率CSBRRWT
| Q4 25 | -6.47× | -504.15× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | -120.92× | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | -140.86× | ||
| Q2 24 | — | -126.56× | ||
| Q1 24 | — | -31.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
RWT
暂无分部数据
